SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Adlai Nortye Group Ltd. (ANL) News

Follow Adlai Nortye Group Ltd. (ANL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ANL Asset equity Sector Markets 90 days 7 Last 8.59 Updated Oct 15, 2026, 12:53 PM UTC Open live news feed Open ANL chart & news
L Adlai Nortye Signs Lilly and Merck Trial Agreements for AN4035 Adlai Nortye said the clinical-trial collaboration and supply agreements will support its Phase 1 trial of AN4035, which is being developed to treat certain tumors. EQUITY | Oct 15, 2026, 12:53 PM UTC L Adlai Nortye enters clinical collaboration with Lilly and Merck KGaA The collaboration will evaluate a combination of AN4035 and cetuximab. EQUITY | Oct 15, 2026, 11:00 AM UTC L Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. NASDAQ:ANL (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovativ NEWS | Sep 30, 2026, 11:08 AM UTC L Jefferies initiates Adlai Nortye Group buy at $31 price target Jefferies initiated coverage on Adlai Nortye Group with a Buy rating and a $31.00/share price target, according to TradingView News via Benzinga. EQUITY | Sep 10, 2026, 12:30 PM UTC L HC Wainwright maintains Adlai Nortye $20 price target HC Wainwright & Co. maintained its $20.00/share price target on Adlai Nortye, according to ratings actions reported by Benzinga via TradingView News. EQUITY | Sep 08, 2026, 04:07 PM UTC L ANL price target set to $49 by Lucid Capital Markets Lucid Capital Markets announced a $49.00/share price target for ANL, according to Benzinga ratings actions. EQUITY | Sep 08, 2026, 12:17 PM UTC M Adlai Nortye announces first dose and FDA IND clearance for AN4035 Adlai Nortye said it dosed its first patient in Australia and received U.S. FDA IND clearance for AN4035, a pan-RAS(ON) inhibitor-based ADC. REGULATION | Sep 08, 2026, 11:01 AM UTC H Adlai Nortye (ANL) reports unaudited first-half 2026 results Adlai Nortye Ltd. (ANL) reports unaudited financial results and highlights for the first half of 2026, alongside recent operational progress. EQUITY | Aug 14, 2026, 11:00 AM UTC M Australia: Adlai Nortye Starts Phase I Trial Adlai Nortye begins Phase I trial for AN4035 EQUITY | Aug 03, 2026, 11:00 AM UTC